<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419974</url>
  </required_header>
  <id_info>
    <org_study_id>20170014</org_study_id>
    <nct_id>NCT04419974</nct_id>
  </id_info>
  <brief_title>Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes</brief_title>
  <official_title>Biomarkers and Genetic Modifiers in a Study of Pre-ataxic and Ataxic SCA3/MJD Carriers (BIGPRO Study) - Astrocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will consist of a prospective observation of subjects in a natural history design.
      The investigators will monitor changes of clinical scales, quality of life, messenger
      ribonucleic acid (mRNA) of candidate genes (CCL11, TNFSF14, FCGR3B, CLC, and SLA) (and their
      peptide products, when possible), and eotaxin and S100B serum levels, in order to determine
      which of them is (are) the most sensitive. Participants will be stratified in three groups:
      ataxic carriers, pre-ataxic carriers and non-carriers (controls).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinocerebellar ataxia type 3, or Machado-Joseph disease (SCA3/MJD), is an autosomal dominant
      neurodegenerative disorder caused by a CAG expansion at ATXN3. The gene product is a 42kDa
      protein called ataxin-3, widely expressed in neurons and peripheral tissues. Physiological
      roles of ataxin-3 include, at least, ubiquitination and regulation of misfolded proteins,
      cytoskeletal organization and focal adhesions development, and transcriptional regulation,
      most often as a transcriptional corepressor. One purpose of the present study is to detect a
      possible association between altered transcription patterns of candidate genes and disease
      progression. On the other hand, previous evidences suggest that the disease process linked to
      polyQ aggregation in neuronal cell (&quot;cell-autonomous process&quot;) might be worsened by what
      happens outside the neuronal cell (&quot;non-cell-autonomous process&quot;). Initial evidences lead to
      the role of astrocytes. This is a major depart from the traditional understanding of
      polyglutamine diseases, and comprises the main focus of the present study.

      The main hypothesis of this study is that the SCA3/MJD clinical features may be in part
      associated to astrocytic processes. In order to test it, peripheral level of LIGHT protein
      (encoded by TNFSF14) and eotaxin (encoded by CCL11) - both expressed in astrocytes -, and of
      S100B (a myelin damage marker), will be measured. The investigators speculate if they can be
      biomarkers of disease progression and of pathological process, even before symptoms onset. In
      case this is positive, their responsiveness to change will be tested to check if it is better
      than those of clinical scales.

      The second aim is to test if disease progression can be associated with changes in the
      transcriptional pattern of candidate genes FCGR3B, CLC and SLA.

      &quot;BIGPRO study - Astrocytes&quot; intends to identify variations in these candidates and validate
      them as SCA3/MJD biomarkers. The study will consist of a prospective observation of subjects
      in a natural history design. Changes in clinical scales, quality of life, messenger
      ribonucleic acid (mRNA) of candidate genes (CCL11, TNFSF14, FCGR3B, CLC, and SLA) (and their
      peptide products, when possible), and eotaxin and S100B serum levels will be monitored in
      order to determine which of them is (are) the most sensitive. Participants will be stratified
      in three groups: ataxic carriers, pre-ataxic carriers and non-carriers (controls). For each
      asymptomatic carrier, the time until start of disease will be estimated according to the
      individual CAG expanded sequence (CAGexp) and subject's age. Clinical scales Scale for the
      Assessment and Rating of Ataxia (SARA), Neurological Examination Scale for SCA (NESSCA),
      International Co-operative Rating Scale (ICARS), Inventory of Non-ataxia Symptoms (INAS), SCA
      Functional Index (SCAFI), Composite Cerebellar Functional Severity Score (CCFS) and Quality
      of Life measurements (EQ-5D and SF-36), will be applied at baseline, at 12 months and at 24
      months, in all subjects (all three groups). Eotaxin, TNFSF14, S100B and mRNAs, will be
      measured in the same moments. Progression rates of all these variables will be estimated
      through mixed-models, including, as covariates, age, group and their interactions.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 18, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum concentrations of Eotaxin</measure>
    <time_frame>24 months</time_frame>
    <description>pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum concentrations of S100B</measure>
    <time_frame>24 months</time_frame>
    <description>Î¼g/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in expression of TNFSF14</measure>
    <time_frame>24 months</time_frame>
    <description>Fold change (FC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in expression of CCL11</measure>
    <time_frame>24 months</time_frame>
    <description>Fold change (FC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EQ-5D-3L (EuroQoL 5 Domains evaluated in 3 levels)</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life scale evaluating 5 domains and a visual analog scale. Domain scores increase with worsening in quality of life. In the visual analog scale, worse scores mean decrease in quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SF-36 (Short-form 36)</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life scale evaluating 8 domains through 36 questions. Domain scores decrease with worsening in quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in expression of FCGR3B</measure>
    <time_frame>24 months</time_frame>
    <description>Fold change (FC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of CLC</measure>
    <time_frame>24 months</time_frame>
    <description>Fold change (FC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in expression of SLA</measure>
    <time_frame>24 months</time_frame>
    <description>Fold change (FC)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">95</enrollment>
  <condition>Spinocerebellar Ataxia Type 3</condition>
  <condition>Machado-Joseph Disease</condition>
  <condition>SCA3</condition>
  <condition>MJD</condition>
  <arm_group>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <description>Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <description>Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Related controls</arm_group_label>
    <description>Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Molecular Diagnosis</intervention_name>
    <description>Double-blind molecular diagnosis for the SCA3/MJD mutation.</description>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical Scales - Baseline</intervention_name>
    <description>SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Draw - Baseline</intervention_name>
    <description>Blood collection on baseline for evaluation of
Candidate genes expression
Serum proteins
Lymphocytic proteins</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quality of Life Assessment - Baseline</intervention_name>
    <description>Participants fill out 2 self-reported quality of life questionnaires.</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical Scales - Follow-up 12 months</intervention_name>
    <description>SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Draw - Follow-up 12 months</intervention_name>
    <description>Blood collection 12 months after baseline for prospective evaluation of
Candidate genes expression
Serum proteins
Lymphocytic proteins</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quality of Life Assessment - Follow-up 12 months</intervention_name>
    <description>Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical Scales - Follow-up 24 months</intervention_name>
    <description>SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Draw - Follow-up 24 months</intervention_name>
    <description>Blood collection 24 months after baseline for prospective evaluation of
Candidate genes expression
Serum proteins
Lymphocytic proteins</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quality of Life Assessment - Follow-up 24 months</intervention_name>
    <description>Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with molecular diagnosis of SCA3/MJD will be recruited from the Medical
        Genetics Service database of Hospital de ClÃ­nicas de Porto Alegre, Brazil, by telephone
        calls or by invitation in the outpatient clinic. First degree relatives of these subjects
        at 50% risk of carrying the mutation will also be invited to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with molecular diagnosis of SCA3/MJD

          -  Individuals at 50% risk of inheriting SCA3/MJD mutation without any clinical
             manifestation

        Exclusion Criteria:

          -  Refusal to sign informed consent

          -  Other diagnosed neurological conditions;

          -  Diabetes Mellitus;

          -  Chronic allergy (asthma, eczema, urticaria)

          -  Eosinophilia on baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura B. Jardim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://bigpro.webnode.com/</url>
    <description>Official project website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCA3/MJD</keyword>
  <keyword>SCA3</keyword>
  <keyword>MJD</keyword>
  <keyword>natural history</keyword>
  <keyword>cytokines</keyword>
  <keyword>astrocytes</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing will be done via direct contact with the Principal Investigator in order to preserve individual participants identities</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will become available after final statistical analysis and data publishing via direct contact with principal investigator</ipd_time_frame>
    <ipd_access_criteria>Investigators and researchers of the area</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

